The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?

OBJECTIVES: Preclinical studies showed that BRAF(V600E) mutation significantly reduced radioiodine uptake and decreased the sensitivity to radioactive iodine (RAI) therapy. However, clinical data regarding its role in therapeutic decision making with respect to RAI therapy are currently insufficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Guohua, Kou, Ying, Liu, Bin, Huang, Rui, Kuang, Anren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282664/
https://www.ncbi.nlm.nih.gov/pubmed/30312216
http://dx.doi.org/10.1097/MNM.0000000000000930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282664/
https://www.ncbi.nlm.nih.gov/pubmed/30312216
http://dx.doi.org/10.1097/MNM.0000000000000930

Ejemplares similares